Aurinia Pharmaceuticals Inc.
Clinical trials sponsored by Aurinia Pharmaceuticals Inc., explained in plain language.
Biopharmaceutical company focused on lupus nephritis treatments.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aritinercept aims to tame myasthenia gravis symptoms
Disease control Recruiting nowThis study tests a new drug, aritinercept, in 81 adults with generalized myasthenia gravis. The drug works by blocking two immune signals (BAFF and APRIL) to reduce disease activity. Researchers are checking if it is safe and if it improves daily living activities compared to a p…
Phase: PHASE1, PHASE2 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Lupus kidney trial aims for faster remission with drug cocktail
Disease control Recruiting nowThis study tests whether adding LUPKYNIS to standard biologic therapies (belimumab, obinutuzumab, or anifrolumab) can quickly improve kidney function in people with lupus nephritis. About 150 adults with biopsy-confirmed lupus kidney disease will receive the combination treatment…
Phase: PHASE4 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC